Search for Clinical Trial Results

Sponsored By

Heredodegenerative Disorders, Nervous System - 2 Studies Found

Status Study
Recruiting Study Name: A Phase II Trial of the Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Patients With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)
Condition:
  • Neoplasms, Nerve Tissue
  • Neurofibromatosis 1